» Authors » Markku S Nieminen

Markku S Nieminen

Explore the profile of Markku S Nieminen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 253
Citations 20858
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tikkanen J, Kentta T, Porthan K, Anttonen O, Eranti A, Aro A, et al.
Heart Rhythm . 2022 Apr; 19(8):1297-1303. PMID: 35472593
Background: QRS duration and corrected QT (QTc) interval have been associated with sudden cardiac death (SCD), but no data are available on the significance of repolarization component (JTc interval) of...
2.
Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, et al.
Card Fail Rev . 2020 Jul; 6:e19. PMID: 32714567
Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In...
3.
Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, et al.
J Cardiovasc Pharmacol . 2020 Jul; 76(1):4-22. PMID: 32639325
Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF)....
4.
Sabell T, Banaszewski M, Lassus J, Nieminen M, Tolppanen H, Jantti T, et al.
ESC Heart Fail . 2020 Mar; 7(2):768-773. PMID: 32163675
Aims: Urgent revascularization is the mainstay of treatment in acute coronary syndrome (ACS) related cardiogenic shock (CS). The aim was to investigate the association of angiographic results with 90-day mortality....
5.
Allonen J, Nieminen M, Sinisalo J
Ann Med . 2020 Mar; 52(3-4):74-84. PMID: 32149544
: Acute coronary syndrome (ACS) patients are widely treated with long-term beta-blocker therapy after cardiac event. Especially for low-risk patients, the benefits of beta-blockers on survival and the optimal therapy...
6.
Jaaskelainen P, Vangipurapu J, Raivo J, Kuulasmaa T, Helio T, Aalto-Setala K, et al.
ESC Heart Fail . 2019 Feb; 6(2):436-445. PMID: 30775854
Aims: Nationwide large-scale genetic and outcome studies in cohorts with hypertrophic cardiomyopathy (HCM) have not been previously published. Methods And Results: We sequenced 59 cardiomyopathy-associated genes in 382 unrelated Finnish...
7.
Lahdentausta L, Paju S, Mantyla P, Buhlin K, Pietiainen M, Tervahartiala T, et al.
J Periodontol . 2018 Nov; 90(5):475-483. PMID: 30447005
Background: Smoking is a risk factor for periodontal disease because of its complex impact on the inflammatory response in the periodontium. We investigated the effect of smoking on salivary periodontal...
8.
Porthan K, Kentta T, Niiranen T, Nieminen M, Oikarinen L, Viitasalo M, et al.
Int J Cardiol . 2018 Oct; 276:125-129. PMID: 30293667
Background: Electrocardiographic (ECG) left ventricular hypertrophy (LVH) is an established risk factor for cardiovascular events. However, limited data is available on the prognostic values of different ECG LVH criteria specifically...
9.
Lovric A, Graner M, Bjornson E, Arif M, Benfeitas R, Nyman K, et al.
Sci Rep . 2018 Sep; 8(1):14200. PMID: 30242179
Non-alcoholic fatty liver disease (NAFLD) is recognized as a liver manifestation of metabolic syndrome, accompanied with excessive fat accumulation in the liver and other vital organs. Ectopic fat accumulation was...
10.
Javanainen T, Sans-Rosello J, Harjola V, Nieminen M, Lassus J, Sionis A, et al.
Catheter Cardiovasc Interv . 2018 Sep; 93(1):1-8. PMID: 30208254
Objectives: The aim was to assess the extent of coronary artery disease and revascularization using baseline SYNTAX Score (bSS) and residual SYNTAX Score (rSS) in patients with cardiogenic shock (CS)...